Hisamitsu Pharmaceutical Management

Management Kriterienprüfungen 2/4

Hisamitsu Pharmaceutical's CEO ist Kazuhide Nakatomi, ernannt in May 2015, hat eine Amtszeit von 9.08 Jahren. besitzt direkt 0.33% der Aktien des Unternehmens, im Wert von ¥915.33M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.1 Jahre bzw. 10.1 Jahre.

Wichtige Informationen

Kazuhide Nakatomi

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	9.2yrs
Eigentum des Geschäftsführers	0.3%
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	9.7yrs

Jüngste Management Updates

Recent updates

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Jun 27

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Jun 13

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Apr 09

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Mar 18

Geschäftsführer

Kazuhide Nakatomi (52 yo)

9.2yrs

Amtszeit

Mr. Kazuhide Nakatomi serves as the President of Hisamitsu Pharmaceutical Co. Inc. since May 2015 and has been Chief Executive Officer since May 2019 and has been Director since May 2007 and served as its...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kazuhide Nakatomi	President	9.2yrs	keine Daten	0.33% ¥ 919.3m
Naruhito Higo	Executive VP	less than a year	keine Daten	keine Daten
Nobuo Tsutsumi	Exe Officer of Legal Affairs	10.2yrs	keine Daten	0.0068% ¥ 18.8m
Kosuke Sugiyama	Executive Managing Director of Human Resources	less than a year	keine Daten	0.018% ¥ 48.8m
Tetsuo Akiyama	Senior Managing Executive Officer	less than a year	keine Daten	keine Daten
Kyu Saito	MD, Executive Officer	no data	keine Daten	0.0095% ¥ 26.3m
Shinichi Murayama	Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director	no data	keine Daten	0.0082% ¥ 22.5m
Mitsutoshi Tsuruta	Senior Executive Officer & GM of Pharmaceutical Business Division	no data	keine Daten	keine Daten
Masaya Okuno	Senior Executive Officer and GM of the Pharmaceuticals & Cosmetics Division	no data	keine Daten	keine Daten
Koji Takiyama	Executive Officer	3.2yrs	keine Daten	0.0041% ¥ 11.3m
Katsuhiko Akiyama	Senior Executive Officer & GM of MN Business Promotion Office	1.5yrs	keine Daten	keine Daten
Tomoya Suzuki	Executive Officer and GM of the Regional Mass Sales Dept of Pharmaceuticals & Cosmetics Division	less than a year	keine Daten	keine Daten

1.0yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von 4530 ist erfahren und erfahren (durchschnittliche Amtszeit: 6 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kazuhide Nakatomi	President	17.2yrs	keine Daten	0.33% ¥ 919.3m
Nobuo Tsutsumi	Exe Officer of Legal Affairs	10.2yrs	keine Daten	0.0068% ¥ 18.8m
Kyu Saito	MD, Executive Officer	11.2yrs	keine Daten	0.0095% ¥ 26.3m
Shinichi Murayama	Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director	10.2yrs	keine Daten	0.0082% ¥ 22.5m
Koji Takiyama	Executive Officer	3.2yrs	keine Daten	0.0041% ¥ 11.3m
Munehiko Hirano	Standing Corporate Auditor	18.2yrs	keine Daten	0.0027% ¥ 7.5m
Nobuyuki Nakatomi	Standing Corporate Auditor	16.2yrs	keine Daten	0.34% ¥ 938.0m
Tetsugo Matsuo	Part-time Outside Independent Director	4.2yrs	keine Daten	0.0014% ¥ 3.7m
Teijiro Furukawa	Independent Outside Director	9.2yrs	keine Daten	keine Daten
Yuichiro Anzai	Part-time Outside Independent Director	4.2yrs	keine Daten	keine Daten
Kentaro Watanabe	Part Time Outside Corporate Auditor	1.2yrs	keine Daten	keine Daten
Tamako Watanabe	Part Time Outside Independent Director	1.2yrs	keine Daten	keine Daten

9.7yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 4530Die Vorstandsmitglieder sind sehr erfahren ( 10 ).

Hisamitsu Pharmaceutical Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Final dividend of JP¥45.00 announced

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.

Full year 2024 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024

Upcoming dividend of JP¥42.50 per share

Price target decreased by 15% to JP¥4,250

Third quarter 2024 earnings released: EPS: JP¥48.25 (vs JP¥37.89 in 3Q 2023)

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter and Provides Dividend Guidance for the Full Year Ending February 29, 2024

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2024 Results on Jan 11, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥42.50 per share at 1.8% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2024 Results on Oct 06, 2023

Price target increased by 16% to JP¥4,450

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.57% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024

Full year 2023 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2024 Results on Jul 13, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥42.25 per share at 2.1% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2023 Results on Apr 13, 2023

Third quarter 2023 earnings released: EPS: JP¥37.89 (vs JP¥14.91 in 3Q 2022)

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023

Price target increased to JP¥3,700

Less than half of directors are independent

Price target increased to JP¥3,700

Consensus forecasts updated

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2023 Results on Jan 12, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.51% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter Ended August 31, 2022, Payable on Nov. 9, 2022; Provides Dividend Guidance for the full year ending February 28, 2023

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2023 Results on Oct 12, 2022

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter and Full Year Ending February 28, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2023 Results on Jul 07, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2023

Upcoming dividend of JP¥42.00 per share

Upcoming dividend of JP¥42.00 per share

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2022 Results on Apr 07, 2022

Consensus EPS estimates fall by 19%

Price target decreased to JP¥3,600

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2022

Second quarter 2022 earnings released: EPS JP¥32.30 (vs JP¥43.82 in 2Q 2021)

Upcoming dividend of JP¥42.00 per share

First quarter 2022 earnings released: EPS JP¥28.90 (vs JP¥1.38 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥113 (vs JP¥228 in FY 2020)

Hisamitsu Pharmaceutical Co., Inc. Provides Earnings Guidance for the Year Ending February 28, 2022

Upcoming Dividend of JP¥41.75 Per Share

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2021 Results on Apr 08, 2021

New 90-day high: JP¥6,430

Revenue and earnings miss expectations

Revenue and earnings miss expectations

Third quarter 2021 earnings released: EPS JP¥24.82

New 90-day high: JP¥6,370

New 90-day high: JP¥6,340

New 90-day high: JP¥6,230

Price target lowered to JP¥4,400

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2021 Results on Jan 13, 2021

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2021 Results on Oct 08, 2020

Geschäftsführer

Amtszeit

Führungsteam